Solvay confirms it is proceeding with an analysis of various options for its pharmaceutical activities

Solvay Group wishes to react to the rumours reported today in a press article

Contacts

Media Relations
Erik De Leye
+32 2 264 1530
Investor Relations
Patrick Verelst
+32 2 264 1540